Arvinas is a private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTACTM, or Proteolysis-Targeting Chimera, works by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins.